NEW HAVEN, Conn., Nov. 9, 2012 /PRNewswire/ --
HCV Connection Media Briefing
Monday, November 12
7:45 a.m. Eastern Standard Time
Sheraton Boston Hotel; 39 Dalton Street, Boston, MA 02199;
Also available by Webcast (link will be provided upon request)
The content of the media briefing will include the following themes and information:
Following the briefing there will be a Question & Answer session with leading experts in HCV including:
Achillion (Nasdaq: ACHN) is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have identified and advanced multiple therapeutic compounds, many with novel mechanisms or attributes. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C (HCV) and resistant bacterial infections. Please visit www.achillion.com for additional information.
SOURCE Achillion Pharmaceuticals, Inc.